Mineralys Therapeutics

Mineralys Therapeutics Advances Hypertension Drug Toward FDA Filing After Strong Clinical Results

RADNOR, PA — Mineralys Therapeutics, Inc. (Nasdaq: MLYS) reported a series of positive clinical milestones and second-quarter 2025 financial results, positioning its lead drug candidate, lorundrostat, for a potential new …

Mineralys Therapeutics Advances Hypertension Drug Toward FDA Filing After Strong Clinical Results Read More